English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The gross and microscopical dimensions of small intestines from 12-week old streptozotocin-diabetic rats receiving no therapeutic intervention were compared with those from animals receiving insulin alone or in conjunction with the aldose reductase inhibitor, ponalrestat. Four regions along each intestine were analysed stereologically. Insulin had significant beneficial effects on body weight as well as on intestinal length, width, surface area and volume. In contrast, ponalrestat did not improve body weight deficits and was associated with crypt hypertrophy and a reduced villous surface/crypt volume ratio. There were interaction effects between insulin and ponalrestat for intestinal length and primary mucosal surface area. All groups displayed significant regional differences in surface area of primary mucosa and volume of muscularis externa. Only untreated diabetic rats failed to reveal regional variation in the surface area and volume of villi. Ratios of villous surface area/crypt volume varied from region-to-region in insulin-treated diabetic rats but not in other groups. The study fails to reveal any beneficial effect of aldose reductase inhibition on the changes in intestinal morphology seen in experimental diabetes.

diabetologia

Small intestinal morphology in experimental diabetic rats: a stereological study on the effects of an aldose reductase inhibitor (ponalrestat) given with or without conventional insulin therapy